Omixon specializes in the analysis of targeted Next Generation Sequencing (NGS) data. Using our Target application suite we offer high resolution HLA typing. We also help scientists and clinicians to investigate challenging genomic regions such as breast cancer susceptibility genes (BRCA1 and BRCA2), cystic fibrosis gene (CFTR), as well as custom panels.
Testimonials
Omixon Blog
The Omixon App in Illumina’s genomics cloud computing and storage platform
It’s a huge pleasure to announce that BaseSpace, Illumina’s genomics cloud computing and storage platform, just became commercially available and one of the first apps was launched by Omixon. The commercial release includes a fully supported BaseSpace Apps store for quick and easy access to Illumina and third-party bioinformatics applications.
By
Hajnalka Hejja, MD
0 comments
Webinar about HLA typing from NGS data
Broadcast date: 29 May 2013, Wednesday
Time: 9.00-10.00 AM PT/ 18.00-19.00 CET
Come and join our CEO, Attila Berces online in a presentation and demo of how Omixon Target HLA typing will bring you value during the analysis of NGS data.
Currently, there are 69 on-going clinical trials investigating HLA as a potential biomarker for safety or efficacy. It appears that beside being the most important marker in transplantation, HLA is becoming a more important biomarker for cancer therapeutic development as well. The analytical performance of NGS-based genetic tests highly depends on the bioinformatics software. Although the current false variant rate can be acceptable for research market, it is simply unsuitable for making clinical decisions. Omixon tailors the analysis for the sequencer, amplification method, primer kit, and the characteristics of the gene target itself. This approach results in a robust and highly accurate method to identify genetic variants.
In this webinar you will learn:
- How to reduce ambiguity and increase resolution
- How to achieve the highest accuracy
- How to use Omixon Target HLA as an HLA-typing tool
- How to increase efficiency by reducing effort, time and cost
Who should attend?
- Scientists and researchers from HLA-typing labs
- Molecular biologists working with NGS
- Medical professionals working in transplantation,oncology and immunology
- Bioinformathics working in transplantaion, oncology and immunology
Presenting: Attila Berces, PhD, CEO of Omixon Biocomputing
A live Q&A session will follow the presentation, offering you the opportunity to put forward your questions.
Reserve your webinar seat here.
By
Hajnalka Hejja, MD
0 comments
